Connect with us

Life Sciences

Biotech venture ‘SuPine Therapeutics’ honored with commendation from Ministry of SMEs and Startups!

SuPine Therapeutics Inc., a UNIST-based biotech venture founded by Professor Jeong Beom Kim in the Department of Life Sciences at UNIST has recently been…

Published

on

This article was originally published by BioEngineering

SuPine Therapeutics Inc., a UNIST-based biotech venture founded by Professor Jeong Beom Kim in the Department of Life Sciences at UNIST has recently been honored with the commendation from the Ministry of SMEs and Startups (MSS) at the 2022 Ulsan Startup Festa, which took place on November 30, 2022.

Professor Jeong Beom Kim (left) and his research team

Credit: UNIST

SuPine Therapeutics Inc., a UNIST-based biotech venture founded by Professor Jeong Beom Kim in the Department of Life Sciences at UNIST has recently been honored with the commendation from the Ministry of SMEs and Startups (MSS) at the 2022 Ulsan Startup Festa, which took place on November 30, 2022.

The award was directly related to his recent research and development efforts in finding prospective cures for the patients with spinal cord injury (SCI), and thus contributing to the development of Korean society through the establishment of SuPine Therapeutics Inc.

Starting with the screening of the opening video under the theme of “Engraving the Spirit of Entrepreneurs,” the event was held in the following orders of the opening performance, awarding of commendations, as well as a tour of the exhibition hall. At the award presentation ceremony, Professor Jeong Beom Kim, founder of SuPine Therapeutics Inc., received the commendation from the Ministry of SMEs and Startups, while President Min-Ki Kim of Cheongmyeong Advanced Materials Co., Ltd.) was given the commendation for startup merit.

A new spinal-cord treatment developed by SuPine Therapeutics Inc. has shown excellent therapeutic effects in animal models of SCI, is pushing for good manufacturing practice (GMP) to perform clinical trials, and is actively carrying out licensing procedures to obtain approval from the Ministry of Food and Drug Safety (MFDS) and the U.S. Food and Drug Administration (FDA).

“I am deeply honored to receive this prestigious award,” said Professor Kim. “Special thanks to UNIST and everyone who supported me from the moment I started my own business.” He adds, “We will do our utmost to translate research findings into real-world clinical practice.”





life sciences


clinical trials

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending